Capecitabine is an orally available prodrug that is activated through a three-step enzymatic metabolic process, initially to 5′-deoxy-5-flu- orocytidine (5′-DFCR), then to 5′-deoxy- 5-fluorouridine (5′-DFUR), and finally to 5-FU by thymidine phosphorylase in tumor tissue (Reigner et al., 2001). Here, TYMP is linked to neoplasm.